High Evidence
Research Overview
CagriSema Research for Type 2 Diabetes
An evidence-based overview of research examining CagriSema in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
REDEFINE-2 evaluated CagriSema in adults with type 2 diabetes and obesity. Results showed 13.7% mean weight loss at 68 weeks (vs 3.4% with placebo). 73.5% of participants achieved HbA1c <=6.5% vs 15.9% with placebo, indicating substantial glycemic control benefit.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CagriSema may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.